linjc16/ctgov huggingface dataset:
Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum

Study Overview
=================
Brief Summary
-----------------
Much experimental data has suggested that thyroid hormones (T3 and T4) may modulate neoplastic cells and that T3/T4 deprivation may remove this stimulus. It is now well established that T3/T4 affects cell division/angiogenesis through binding to integrin avb3, commonly over-expressed on many cancer cells. In the experimental settings, mimicking hypothyroidism in the cells is a difficult task. Currently, the use of charcoal stripped serum is used. Using this method, the serum is stripped not only from T3 and T4, as intended, but also from central and important cytokines and growth factor. This leads to a reduced rate of cancer cell proliferation and thus, does not reflect the natural environment in which cancer cells residue under hypothyroid conditions. The investigators aim to characterize and establish the effects of serum from hypothyroid patients on the proliferation/viability of a variety of cancer cell models.

Official Title
-----------------
Association Between Cancer Cells and Normal Vs. Low Levels of Thyroid Hormones in the Serum

Conditions
-----------------
Thyroid Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hypothyroid state Exclusion Criteria: Non hypothyroid state

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hypothyroid<br> | |
| Non hypothyroid<br> | |
| Healthy subjects<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypothyroid and non hypothyroid
Asthma and Allergy Screening AA2000 (Cross Sectional)

Study Overview
=================
Brief Summary
-----------------
Asthma screening of 493 asthma patients

Detailed Description
-----------------
Questionnaire, and testing

Official Title
-----------------
Asthma and Allergy Screening AA2000 (Cross Sectional)

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Usual care versus primary care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: respiratory symptoms suggestive for asthma - Exclusion Criteria:COPD -

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| asthma and rhinitis<br>Screening of patients with upper and lower airway symptoms | Drug: Usual care versus primary care<br>* RCT study<br>* Other names: RCT study, usuar care in specialist setting (GINA and ARIA);|
| asthma and rhintis follow-up<br>same Group as screened in 2000, was followed up three years later | Drug: Usual care versus primary care<br>* RCT study<br>* Other names: RCT study, usuar care in specialist setting (GINA and ARIA);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ACQ | Questionnaire based | 2004 | 
| AQLQ | Questionnaire based | 2004 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FEV1 | Lung function | 2004 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
asthma, airway hyperresponsiveness, asthma management
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to prove the bioequivalence of Letrozole Tablet under fasted conditions.

Official Title
-----------------
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Letrozole Tablets Under Fasted Conditions

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: Letrozole
* Drug: Letrozole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to letrozole or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Letrozole<br>2.5 mg tablet | Drug: Letrozole<br>* 2.5 mg Tablet<br>* Other names: Femara;|
| Active Comparator: Femara<br>2.5 mg tablet | Drug: Letrozole<br>* 2.5 mg tablet<br>* Other names: Femara;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bioequivalence determined by statistical comparison Cmax |  | 31 days |
Comparison of RT in Patients With Sleep Apnea With and Without Complaints of Daytime Sleepiness

Study Overview
=================
Brief Summary
-----------------
Not all patients with the Obstructive Sleep Apnea Syndrome (OSAS), mostly mild, have excessive daytime sleepiness. Sleep fragmentation provides the performance decrease with increasing reaction time to external stimuli and correlates with excessive sleepiness. So, the study aims at assessing the effect of sleep fragmentation on the Reaction Time and it's maintenance in patients with OSAS compared with healthy, to better clarify were patients with and without somnolence differ. For that, will be recruited 30 male volunteers aged between 20 and 50 year old to participate in the study. They will be distributed in three groups: CONTROL (without symptoms of sleepiness and apnea and hypopnea index (AHI) less than 5), SS (with AHI between 5 and 15 without symptoms of somnolence) and group CS (with AHI between 5 and 15 with symptoms of somnolence). The groups will undergo a polysomnography and subsequently, the Test and Maintenance of Wakefulness and PVT Battery Tests. The reaction time will be compared, as well as the ability to keep the reaction time over time between groups to see whether there is a difference between the motor performance throughout the day and the perception of sleepiness.

Official Title
-----------------
Behavior of Psychomotor Vigilance Task Performance in Subjects With Obstructive Sleep Apnea With and Without Complaints of Daytime Sleepiness

Conditions
-----------------
Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Man Aged between 20 and 45 years old BMI between 20-30 Exclusion Criteria: Cigarette Smoke Drug intake Other sleep disturbances

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CTR<br>Control group | |
| ASS<br>Apnea without complaints group | |
| ACS<br>SAOS Group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Apnea, PVT, Reaction Time
Magnesium Administration After Cardioplegic Arrest With Del Nido Cardioplegia

Study Overview
=================
Brief Summary
-----------------
The cardioplegia solution of choice in many pediatric cardiac congenital programs is the del Nido solution. While many cardioplegia solutions provide diastolic arrest, del Nido provides a longer period of time between doses of cardioplegia. Many of the other cardioplegia solutions do not incorporate magnesium into the constituents, but del Nido does. Routine practice at CCHMC is to dose 25 mg/kg magnesium upon removal of the heart cross-clamp to protect against hypomagnesemia and associated arrhythmias. However, with the incorporation of magnesium in the del Nido solution, it may not be necessary to administer magnesium post cross-clamp and it could in fact be detrimental if the magnesium level is too high. This observational study will examine the magnesium levels prior to and after cross-clamp removal under our current process. The magnesium levels measured after the administration of del Nido cardioplegia and prior to cross-clamp removal will help inform our current practice.

Official Title
-----------------
Magnesium Administration After Cardioplegic Arrest With Del Nido Cardioplegia

Conditions
-----------------
Del Nido Cardioplegia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing cardiac surgery requiring CPB and cardioplegic arrest with del Nido cardioplegia solution. Patients planned to receive post cross-clamp dose of 25 mg/kg magnesium sulfate.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All Participants<br>All patients undergoing CPB with dNC cardioplegic arrest shall have two magnesium levels measured. The first sample shall be taken prior to magnesium administration and within 30 minutes of cross-clamp removal. The second sample will be drawn 10 +/- 5 minutes after cross-clamp removal and magnesium administration. Magnesium levels will be analyzed and compared against normally expected values. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Examine magnesium levels prior to and after cross-clamp. | The primary objective of this study is to examine magnesium levels prior to and after cross-clamp. | 24 months from start of enrollment. |
Intraocular Pressure After Preserflo / Innfocus Microshunt Implantation vs Trabeculectomy

Study Overview
=================
Brief Summary
-----------------
The aim of this project is to compare trabeculectomy with Preserflo / Innfocus Microshunt in patients with Primary Angle Open Glaucoma and Pseudoexfoliation Glaucoma regarding the reduction of intraocular pressure.

Detailed Description
-----------------
The study is a prospective, randomized, monocentric, part blinded, controlled non-inferiority study of glaucoma patients.

Official Title
-----------------
Intraocular Pressure After Preserflo /Innfocus Microshunt vs Trabeculectomy: a Prospective, Randomised Control-trial (PAINT-Study)

Conditions
-----------------
Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma

Intervention / Treatment
-----------------
* Device: Preserflo / Innfocus Microshunt
* Other: Trabeculectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Primary open angle glaucoma or pseudoexfoliation glaucoma medically uncontrollable intraocular pressure or intolerance of topical therapy negative urine/serum pregnancy test of women in childbearing age signed and dated informed consent Exclusion Criteria: previous incisional glaucoma procedure on affected eye pregnancy, nursing period Patients in military service, training periods and civil service Participation in another clinical trail pre-existing ocular pathologies: high myopia (refraction ≥8.00 D), thin conjunctiva

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Microshunt<br>Patients will be treated with Preserflo / Innfocus Microshunt (Santen Pharmaceutical Co., Ltd.). | Device: Preserflo / Innfocus Microshunt<br>* The Microshunt features an 8.5-mm tube with an outer diameter of 350 µm and a 70-µm diameter lumen. Implantation creates a subconjunctival bleb and lowers intraocular pressure by increasing aqueous humor outflow.<br>|
| Active Comparator: Trabeculectomy<br>Patients will be treated with trabeculectomy. | Other: Trabeculectomy<br>* Trabeculectomy is the most commonly performed surgical procedure and is considered the gold standard.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in intraocular pressure | The primary endpoint is the difference between intraocular pressure after microshunt implantation vs trabeculectomy. | 1 year |
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in buprenorphine-naloxone maintained volunteers

Detailed Description
-----------------
Ongoing study - results not available at this time

Official Title
-----------------
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1

Conditions
-----------------
Heroin Dependence, Opioid-Related Disorders

Intervention / Treatment
-----------------
* Drug: Opioid-Related Disorders


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals must be at least 18 yrs of age, currently opioid dependent and meet FDA criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use. Exclusion Criteria: Individuals with evidence of anti active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Opioid-Related Disorders|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective dose estimate |  |  | 
| Observed withdrawal rating |  |  | 
| Opioid agonist rating |  |  | 
| Opioid antagonist rating |  |  | 
| Pupil diameter |  |  | 
| Analog rating scale for drug effects |  |  | 
| Drug effect characteristics |  |  | 
| Drug/Money Preferences |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
drug dependence
Effect of Breathing Circuits on Intraoperative Body Temperature

Study Overview
=================
Brief Summary
-----------------
To evaluate differences in intraoperative body temperature between heated huimid breathing circuit and conventional breathing circuit

Conditions
-----------------
Brain Tumor

Intervention / Treatment
-----------------
* Device: Group C
* Device: Group E
* Device: Group M


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 18-70 years, ASA I or II patients scheduled for craniotomy under general anesthesia Exclusion Criteria: ASA III or IV Duration of anesthesia time less than 4 hours emergency operation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Group C<br>non-heated, non-humidified conventional breathing circuit was used in group C patient | Device: Group C<br>* non-heated, non-humidified conventional breathing circuit was used in group C patient<br>* Other names: conventional circuit;|
| Experimental: Group E<br>breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient | Device: Group E<br>* breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient<br>* Other names: Evaqua™ Breathing Circuits manufactured by Fischer & Paykel;|
| Experimental: Group M<br>Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient | Device: Group M<br>* Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient<br>* Other names: Mega Acer kit manufactured by Acemedical,Seoul Korea;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| trend of changes on body temperature | Investigate differences on core body temperature among different kinds of circuit (heated-humid circuit, humid circuit, conventional circuit) | from the point of postintubation up to 5 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| total duration of airwarmer(Bair-Hurgger warming unit) using time | investigate the total duration of airwarmer using time | from the point of postintubation up to 5hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
core body temperature, humidity, circuit temperature
A Multiple-center Study on the Effect of Different Ways of Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With More Than 50% Solid Components

Study Overview
=================
Brief Summary
-----------------
A multiple-center study on the effect of different ways of lymph node dissection on the prognosis of less than 3cm ground glass nodules with more than solid components

Official Title
-----------------
Zhongshan Hospital

Conditions
-----------------
Progression

Intervention / Treatment
-----------------
* Procedure: Lymphadenectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged between 18 and 75 years; GGO is diagnosed by lung CT and failure to subside after 3 months (the patient having been re-examined by thin-section CT); The maximum diameter of the GGO is smaller than 3cm; The maximum diameter of the solid component in the GGO is more than 50%; The patient is able to undergo the lobectomy The patient is able to understand and comply with the study and has provided written informed consent. Exclusion Criteria: - Patients meeting any of the following criteria are not eligible for this trial: Patients with a history of using immunosuppressive or hormonal drugs; Patients receiving radiotherapy or chemotherapy; Patients who fail to comply with our follow-up strategy; Other situations that are not in conformity with the standards and requirements of this trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Selective lymphadenectomy<br> | Procedure: Lymphadenectomy<br>* Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group<br>|
| No Intervention: Systematic lymph node dissection<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival (OS) | five year overall survival | 5 years |
Transversus Abdominis Plane Block After Robot-assisted Laparocopic Hysterectomy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effectiveness of Transversus Abdominis Plane (TAP) block as a part of a multimodal postoperative pain management after robot-assisted laparoscopic hysterecomy.

Official Title
-----------------
Effekt of Transversus Abdominis Plane (TAP) Block After Robot-assisted Laparocopic Hysterectomy

Conditions
-----------------
Hysterectomy

Intervention / Treatment
-----------------
* Procedure: TAP block
* Procedure: Placebo TAP block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-80 BMI 17-40 Written consent Can cooperate Exclusion Criteria: Drug and alcohol abuse Consumption of opioids Drug allergy Infection at insertion point of needle

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TAP block<br>TAP block with ropivacaine | Procedure: TAP block<br>* Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %<br>* Other names: Naropin 0.5%;|
| Placebo Comparator: Placebo TAP block<br>Sham block with saline | Procedure: Placebo TAP block<br>* Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane<br>* Other names: Saline 0.9%;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total opioid consumption | Opioid consumption via PCA-pump | 0-24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain during rest and cough | VAS-pain score at rest and at cough | 1,2,4,8,18 and 24 hours | 
| Postoperative nausea and vomiting | Nausea score 0-3 No. of vomits | 1,2,4,8,18 and 24 hours |